An investigational new agent called tasquinimod may help increase survival in men with metastatic prostate cancer.
This oral agent has been found to extend progression-free survival by a mean of 7.6 months compared with 3.3 months for placebo.
John Schieszer has the latest on this new agent in today’s Medical Minute.
Next post in The Medical Minute
Log in to continue reading this article.
Don’t miss out on today’s top content on Renal & Urology News. Register for free and gain unlimited access to:
- Clinical News, with personalized daily picks for you
- Case Studies
- Conference Coverage
- Full-Length Features
- Drug Monographs
- And More
Want to read more?
Please login or register first to view this content.